Page 28 - MemoriaEHD-Eng

SCIENTIFIC PROGRAMS

Prospective, controlled and randomized study of colorectal cancer

screening in a medium-risk population: detection of occult blood in
feces by means of an immunological test every 2 years vs. colonos-

copy (ColonPrev study)

PI: Antoni Castells and Luis Bujanda

Today there are various strategies accepted for colorectal cancer screening in a me-

dium-risk population (men and women over 50 years of age, without any personal or
family history of this disease). However, the most effective and efficient strategy is

unknown because there are no studies comparing them directly.

Objectives

To compare the efficacy of the detection of occult blood in feces by means of biennial
immunological testing with colonoscopy every 10 years in the medium-risk population

(individuals over 50 years of age without any additional risk factors) in relation to:

Reduction of mortality due to colorectal cancer in 10 years (primary objective) and
rate of detection of advanced colorectal neoplasias (high-risk colorectal cancer and

adenomas).

Translational research for integral genomic analysis of conventio-

nal fibrolamellar hepatocellular carcinoma and intrahepatic cholan-
giocarcinoma (CHC).

PI: Josep M. Llovet and Jordi Bruix

The prognostic assessment of patients with hepatocellular carcinoma or with cholan-

giocarcinoma today is based on conventional morphological criteria. Logically, tumor
phenotype depends on the molecular disorders and, therefore, characterizing mole-

cular anomalies in patients with this neoplasia and correlating them with progression

must enable developing prediction models based on genetic signatures, as well as
stratifying patients according to the molecular pattern that should be responsible for

the response to treatment.

The results obtained until now have contributed to stratifying patients according to

genomic patterns. This data was not generated from collections of surgically treated
tumors, and the challenge today is to validate the usefulness and reproducibility of the

information obtained from advanced stage tumor biopsy samples. Advanced tumor he-
terogeneity suggests that biopsy-based information may be limited. Therefore, studies

have been designed to explore the usefulness of detecting circulating tumor cells and

to obtain molecular profiles based on said studies. Colloquially speaking, this approach 13
is referred to as “liquid biopsy”.
20
T
R
PO
E
L R
A
Treatment of hepatocarcinoma by means of anti-PD1 monoclonal NU
N
antibodies.
A
/
HD
PI: Ignacio Melero y Bruno Sangro.
E
ER
Advanced stage hepatocarcinoma has a very poor prognosis. Sorafenib is a biological IB
agent that significantly increases advanced stage hepatocarcinoma patient survival.
C

28